{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:35:28Z","timestamp":1789785328365,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2015,1,25]],"date-time":"2015-01-25T00:00:00Z","timestamp":1422144000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00262-015-1658-8","type":"journal-article","created":{"date-parts":[[2015,1,24]],"date-time":"2015-01-24T07:38:51Z","timestamp":1422085131000},"page":"467-478","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Local expression of complement factor I in breast cancer cells correlates with poor survival and recurrence"],"prefix":"10.1007","volume":"64","author":[{"given":"Marcin","family":"Okroj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emelie","family":"Holmquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lola","family":"Anagnostaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jirstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Blom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,1,25]]},"reference":[{"key":"1658_CR1","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/ni.1923","volume":"11","author":"D Ricklin","year":"2010","unstructured":"Ricklin D, Hajishengallis G, Yang K, Lambris JD (2010) Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11:785\u2013797. doi: 10.1038\/ni.1923","journal-title":"Nat Immunol"},{"key":"1658_CR2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.ctrv.2012.10.008","volume":"39","author":"M Okroj","year":"2013","unstructured":"Okroj M, Osterborg A, Blom AM (2013) Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies. Cancer Treat Rev 39:632\u2013639. doi: 10.1016\/j.ctrv.2012.10.008","journal-title":"Cancer Treat Rev"},{"key":"1658_CR3","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0161-5890(99)00115-7","volume":"36","author":"K Jurianz","year":"1999","unstructured":"Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z, Kirschfink M (1999) Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 36:929\u2013939","journal-title":"Mol Immunol"},{"key":"1658_CR4","doi-asserted-by":"crossref","first-page":"45093","DOI":"10.1074\/jbc.M407558200","volume":"279","author":"L Mark","year":"2004","unstructured":"Mark L, Lee WH, Spiller OB, Proctor D, Blackbourn DJ, Villoutreix BO, Blom AM (2004) The Kaposi\u2019s sarcoma-associated herpesvirus complement control protein mimics human molecular mechanisms for inhibition of the complement system. J Biol Chem 279:45093\u201345101","journal-title":"J Biol Chem"},{"key":"1658_CR5","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.4049\/jimmunol.178.9.5991","volume":"178","author":"D Ajona","year":"2007","unstructured":"Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R (2007) Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol 178:5991\u20135998","journal-title":"J Immunol"},{"key":"1658_CR6","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/ni.1655","volume":"9","author":"MM Markiewski","year":"2008","unstructured":"Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD (2008) Modulation of the antitumor immune response by complement. Nat Immunol 9:1225\u20131235. doi: 10.1038\/ni.1655","journal-title":"Nat Immunol"},{"key":"1658_CR7","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.4049\/jimmunol.1201654","volume":"189","author":"L Corrales","year":"2012","unstructured":"Corrales L, Ajona D, Rafail S, Lasarte JJ, Riezu-Boj JI, Lambris JD, Rouzaut A, Pajares MJ, Montuenga LM, Pio R (2012) Anaphylatoxin c5a creates a favorable microenvironment for lung cancer progression. J Immunol 189:4674\u20134683. doi: 10.4049\/jimmunol.1201654","journal-title":"J Immunol"},{"key":"1658_CR8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0161-5890(01)00045-1","volume":"38","author":"G Schlaf","year":"2001","unstructured":"Schlaf G, Demberg T, Beisel N, Schieferdecker HL, Gotze O (2001) Expression and regulation of complement factors H and I in rat and human cells: some critical notes. Mol Immunol 38:231\u2013239","journal-title":"Mol Immunol"},{"key":"1658_CR9","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1146\/annurev-immunol-032713-120154","volume":"32","author":"VM Holers","year":"2014","unstructured":"Holers VM (2014) Complement and its receptors: new insights into human disease. Ann Rev Immunol 32:433\u2013459. doi: 10.1146\/annurev-immunol-032713-120154","journal-title":"Ann Rev Immunol"},{"key":"1658_CR10","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3892\/ijmm_00000346","volume":"25","author":"C Stover","year":"2010","unstructured":"Stover C (2010) Dual role of complement in tumour growth and metastasis (review). Int J Mol Med 25:307\u2013313","journal-title":"Int J Mol Med"},{"key":"1658_CR11","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0167-4781(98)00189-4","volume":"1442","author":"JO Minta","year":"1998","unstructured":"Minta JO, Fung M, Paramaswara B (1998) Transcriptional and post-transcriptional regulation of complement factor I (CFI) gene expression in Hep G2 cells by interleukin-6. Biochim Biophys Acta 1442:286\u2013295","journal-title":"Biochim Biophys Acta"},{"key":"1658_CR12","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.4049\/jimmunol.150.9.4052","volume":"150","author":"V Vetvicka","year":"1993","unstructured":"Vetvicka V, Reed W, Hoover ML, Ross GD (1993) Complement factors H and I synthesized by B cell lines function to generate a growth factor activity from C3. J Immunol 150:4052\u20134060","journal-title":"J Immunol"},{"key":"1658_CR13","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.4049\/jimmunol.149.4.1381","volume":"149","author":"P Gasque","year":"1992","unstructured":"Gasque P, Julen N, Ischenko AM, Picot C, Mauger C, Chauzy C, Ripoche J, Fontaine M (1992) Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 149:1381\u20131387","journal-title":"J Immunol"},{"key":"1658_CR14","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1002\/eji.1830251238","volume":"25","author":"J Legoedec","year":"1995","unstructured":"Legoedec J, Gasque P, Jeanne JF, Fontaine M (1995) Expression of the complement alternative pathway by human myoblasts in vitro: biosynthesis of C3, factor B, factor H and factor I. Eur J Immunol 25:3460\u20133466. doi: 10.1002\/eji.1830251238","journal-title":"Eur J Immunol"},{"key":"1658_CR15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.molimm.2007.04.025","volume":"45","author":"M Okroj","year":"2008","unstructured":"Okroj M, Hsu YF, Ajona D, Pio R, Blom AM (2008) Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol 45:169\u2013179","journal-title":"Mol Immunol"},{"key":"1658_CR16","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/jid.2014.376","volume":"135","author":"P Riihila","year":"2015","unstructured":"Riihila P, Nissinen L, Farshchian M, Kivisaari A, Ala-Aho R, Kallajoki M, Grenman R, Meri S, Peltonen S, Peltonen J, Kahari VM (2015) Complement factor I promotes progression of cutaneous squamous cell carcinoma. J Invest Dermatol 135:579\u2013588. doi: 10.1038\/jid.2014.376","journal-title":"J Invest Dermatol"},{"key":"1658_CR17","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.molimm.2006.10.005","volume":"44","author":"SC Nilsson","year":"2007","unstructured":"Nilsson SC, Karpman D, Vaziri-Sani F, Kristoffersson AC, Salomon R, Provot F, Fremeaux-Bacchi V, Trouw LA, Blom AM (2007) A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. Mol Immunol 44:1835\u20131844. doi: 10.1016\/j.molimm.2006.10.005","journal-title":"Mol Immunol"},{"key":"1658_CR18","doi-asserted-by":"crossref","first-page":"e34852","DOI":"10.1371\/journal.pone.0034852","volume":"7","author":"S Malm","year":"2012","unstructured":"Malm S, Jusko M, Eick S, Potempa J, Riesbeck K, Blom AM (2012) Acquisition of complement inhibitor serine protease factor I and its cofactors C4b-binding protein and factor H by Prevotella intermedia. PLoS ONE 7:e34852. doi: 10.1371\/journal.pone.0034852","journal-title":"PLoS ONE"},{"key":"1658_CR19","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/eji.200939280","volume":"40","author":"SC Nilsson","year":"2010","unstructured":"Nilsson SC, Kalchishkova N, Trouw LA, Fremeaux-Bacchi V, Villoutreix BO, Blom AM (2010) Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. Eur J Immunol 40:172\u2013185. doi: 10.1002\/eji.200939280","journal-title":"Eur J Immunol"},{"key":"1658_CR20","doi-asserted-by":"crossref","first-page":"RESEARCH0034","DOI":"10.1186\/gb-2002-3-7-research0034","volume":"3","author":"J Vandesompele","year":"2002","unstructured":"Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034","journal-title":"Genome Biol"},{"key":"1658_CR21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/978-1-62703-724-2_15","volume":"1100","author":"SC Nilsson","year":"2014","unstructured":"Nilsson SC, Blom AM (2014) Purification and functional characterization of factor I. Methods Mol Biol 1100:177\u2013188. doi: 10.1007\/978-1-62703-724-2_15","journal-title":"Methods Mol Biol"},{"key":"1658_CR22","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1042\/bj0890114","volume":"89","author":"FC Greenwood","year":"1963","unstructured":"Greenwood FC, Hunter WM, Glover JS (1963) The preparation of I-131-labelled human growth hormone of high specific radioactivity. Biochem J 89:114\u2013123","journal-title":"Biochem J"},{"key":"1658_CR23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-62703-724-2_14","volume":"1100","author":"FC Mohlin","year":"2014","unstructured":"Mohlin FC, Blom AM (2014) Purification and functional characterization of C4b-binding protein (C4BP). Methods Mol Biol 1100:169\u2013176. doi: 10.1007\/978-1-62703-724-2_14","journal-title":"Methods Mol Biol"},{"key":"1658_CR24","doi-asserted-by":"crossref","first-page":"9212","DOI":"10.1158\/0008-5472.CAN-08-1135","volume":"68","author":"K Helczynska","year":"2008","unstructured":"Helczynska K, Larsson AM, Mengelbier LH, Bridges E, Fredlund E, Borgquist S, Landberg G, Pahlman S, Jirstrom K (2008) Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer. Cancer Res 68:9212\u20139220. doi: 10.1158\/0008-5472.CAN-08-1135","journal-title":"Cancer Res"},{"key":"1658_CR25","first-page":"1421","volume":"39","author":"KJ Svensson","year":"2011","unstructured":"Svensson KJ, Christianson HC, Kucharzewska P, Fagerstrom V, Lundstedt L, Borgquist S, Jirstrom K, Belting M (2011) Chondroitin sulfate expression predicts poor outcome in breast cancer. Int J Oncol 39:1421\u20131428. doi: 10.3892\/ijo.2011.1164","journal-title":"Int J Oncol"},{"key":"1658_CR26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/jcp.2006.040378","volume":"61","author":"S Borgquist","year":"2008","unstructured":"Borgquist S, Holm C, Stendahl M, Anagnostaki L, Landberg G, Jirstrom K (2008) Oestrogen receptors alpha and beta show different associations to clinicopathological parameters and their co-expression might predict a better response to endocrine treatment in breast cancer. J Clin Pathol 61:197\u2013203. doi: 10.1136\/jcp.2006.040378","journal-title":"J Clin Pathol"},{"key":"1658_CR27","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1200\/JCO.2005.08.126","volume":"23","author":"L Ryden","year":"2005","unstructured":"Ryden L, Jirstrom K, Bendahl PO, Ferno M, Nordenskjold B, Stal O, Thorstenson S, Jonsson PE, Landberg G (2005) Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 23:4695\u20134704. doi: 10.1200\/JCO.2005.08.126","journal-title":"J Clin Oncol"},{"key":"1658_CR28","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jmoldx.2011.08.002","volume":"14","author":"F Wang","year":"2012","unstructured":"Wang F, Flanagan J, Su N, Wang LC, Bui S, Nielson A, Wu X, Vo HT, Ma XJ, Luo Y (2012) RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues. J Mol Diagn 14:22\u201329. doi: 10.1016\/j.jmoldx.2011.08.002","journal-title":"J Mol Diagn"},{"key":"1658_CR29","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0161-5890(02)00213-4","volume":"39","author":"AM Blom","year":"2003","unstructured":"Blom AM, Kask L, Dahlb\u00e4ck B (2003) CCP1-4 of the C4b-binding protein a-chain are required for factor I mediated cleavage of C3b. Mol Immunol 39:547\u2013556","journal-title":"Mol Immunol"},{"key":"1658_CR30","first-page":"161","volume":"39","author":"T Cui","year":"2011","unstructured":"Cui T, Chen Y, Kn\u00f6sel T, Yang L, Z\u00f6ller K, Galler K, Berndt A, Mihlan M, Zipfel PF, Petersen I (2011) Human complement factor H is a novel diagnostic marker for lung adenocarcinoma. Int J Oncol 39:161\u2013168. doi: 10.3892\/ijo.2011.1010","journal-title":"Int J Oncol"},{"key":"1658_CR31","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s00262-009-0685-8","volume":"58","author":"M Okroj","year":"2009","unstructured":"Okroj M, Corrales L, Stokowska A, Pio R, Blom AM (2009) Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. Cancer Immunol Immunother 58:1771\u20131880. doi: 10.1007\/s00262-009-0685-8","journal-title":"Cancer Immunol Immunother"},{"key":"1658_CR32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0161-5890(98)00052-2","volume":"35","author":"CG Ullman","year":"1998","unstructured":"Ullman CG, Chamberlain D, Ansari A, Emery VC, Haris PI, Sim RB, Perkins SJ (1998) Human complement factor I: its expression by insect cells and its biochemical and structural characterisation. Mol Immunol 35:503\u2013512","journal-title":"Mol Immunol"},{"key":"1658_CR33","doi-asserted-by":"crossref","first-page":"6100","DOI":"10.1158\/1078-0432.CCR-10-1533","volume":"16","author":"KM O\u2019Brien","year":"2010","unstructured":"O\u2019Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC (2010) Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 16:6100\u20136110. doi: 10.1158\/1078-0432.CCR-10-1533","journal-title":"Clin Cancer Res"},{"key":"1658_CR34","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1359-6446(03)02686-2","volume":"8","author":"LL Munn","year":"2003","unstructured":"Munn LL (2003) Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 8:396\u2013403","journal-title":"Drug Discov Today"},{"key":"1658_CR35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2249.1993.tb03377.x","volume":"92","author":"GD Ross","year":"1993","unstructured":"Ross GD, V\u0115tvicka V (1993) CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin Exp Immunol 92:181\u2013184","journal-title":"Clin Exp Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-015-1658-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-015-1658-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-015-1658-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T14:20:36Z","timestamp":1690899636000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-015-1658-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,25]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["1658"],"URL":"https:\/\/doi.org\/10.1007\/s00262-015-1658-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1,25]]}}}